Leapfrog Bio is a seed stage company focused on developing precision therapeutics targeting solid tumors caused by loss of function mutations. Since inception in 2019 the company has developed and validated a novel pharmacogenomic platform that utilizes the biology of synthetic lethality to screen clinical stage assets. To date the company has discovered 12 novel synthetically lethal drug and sensitizing mutation combinations and filed IP around 4 of these discovers. The company has identified two lead molecules to advance into clinical development in 2024. The company is currently raising a series A round to fund its lead program moving into phase 2a clinical trials in 3 solid tumor types in late 2024. Additionally the company will advance a second program to phase 2 ready and build a deep preclinical pipeline from the series A raise.